Mathurin Fumery @MatFume X Profile

Mathurin Fumery

@MatFume

Followers

674

Following

4K

Media

39

Statuses

1K

MD, PhD, Professor of gastroenterology, EPIMAD registry, focus on IBD, Amiens-Picardie university hospital, France

Amiens, France

Joined September 2014

Don't wanna be here? Send us removal request.

Mathurin Fumery

@MatFume

12 days

New EPIMAD study.Long term comparaison of the natural history of ileal Crohn, colonic Crohn and UC. Two or three diseases ?.@CHUAmiens @CHURouen @UPJV_Univ.

0

1

9

Mathurin Fumery

@MatFume

19 days

Check out our new study evaluating the impact of complete endoscopic healing (EH, CDEIS=0) on long term outcomes in Crohn's Disease.▶️ Multicenter prospective study.▶️ Risk of therapeutic failure and hospitalisation significantly higher with partial EH.

0

5

14

Mathurin Fumery

@MatFume

6 months

RT @PGetaid: UN NOUVEAU PODCAST DISPONIBLE ! . Cette semaine, le Dr Maria Nachury nous explique entre autres la monothérapie ou la combo-….

0

1

0

Mathurin Fumery

@MatFume

6 months

RT @PGetaid: 📢 Étude I-CARE 2 : 500 patients inclus ! 🎉. 🔹 Incluez vos patients débutant une biothérapie ou un JAKi dès maintenant. ⚠️ Ob….

0

2

0

Mathurin Fumery

@MatFume

7 months

RT @PGetaid: NE RATEZ PAS LA SAISON 2 DES PODCASTS DU GETAID ! . Les épisodes 1 et 2 sont déjà disponibles !!!. Un nouvel épisode sera mis….

0

1

0

Mathurin Fumery

@MatFume

7 months

RT @AssisesMICI: SAVE THE DATE ! .Le vendredi 24 janvier 2025 se déroulera la 18ème édition des Assises Nationales des MICI qui auront lieu….

0

2

0

Mathurin Fumery

@MatFume

9 months

RT @Rob__Brierley: New @LancetRH_Europe - Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France….

0

13

0

Mathurin Fumery

@MatFume

10 months

RT @JCC_IBD: The GETAID: 40 years of a family story in IBD. Laharie et al. @BouhnikYoram @JeanFredericCo1 @MatFume @PeyrinBiroulet https:/….

0

2

0

Mathurin Fumery

@MatFume

11 months

RT @JeanFredericCo1: Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms. http….

0

27

0

Mathurin Fumery

@MatFume

11 months

RT @PGetaid: Le Séminaire GETAID-REMIND aura lieu le jeudi 5 décembre et le vendredi 6 décembre 2024 ! 🎉. Les inscriptions sont ouvertes 😃….

0

4

0

Mathurin Fumery

@MatFume

11 months

RT @PGetaid: Les inscriptions pour la Masterclass du GETAID sont lancées ! 🥳. Au programme : mises au point, échanges avec les experts, ate….

0

2

0

Mathurin Fumery

@MatFume

11 months

RT @afaCrohnRCH: Vous souhaitez participer au prochain @semideparis qui aura lieu le dimanche 9 mars 2025 ? Pensez au dossard solidaire AF….

0

3

0

Mathurin Fumery

@MatFume

1 year

Is non-invasive (calpro ? IUS ?) assessment of mucosal healing really feasible in UC and CD? Check out our news studies @BrazierFranck @ClaraYzet.@CHUAmiens @UPJV_Univ.

0

2

12

Mathurin Fumery

@MatFume

1 year

RT @DrMikeDolinger: The 1st!! @AmerGastroAssn Clinical Practice Update on the role of intestinal ultrasound in IBD led by @malloc_doc @Shir….

0

17

0

Mathurin Fumery

@MatFume

1 year

RT @JCC_IBD: Early #IUS in severe ulcerative colitis identifies patients at increased risk of 1-year treatment failure and colectomy Ilvema….

0

11

0

Mathurin Fumery

@MatFume

1 year

RT @alearmuzzi: How long you should practice to become confident on IUS? The learning curve indicate around 80 to 100 examination to acqui….

0

3

0

Mathurin Fumery

@MatFume

1 year

@NordicPharma.

0

Mathurin Fumery

@MatFume

1 year

Important milestone for the COMET trial evaluating the best combination with adalimumab (aza vs metho) in Crohn's disease: 50 patients included! Thanks to all the centers!.@PGetaid @PeyrinBiroulet @freseniuskabifr @snfge @CHUAmiens

1

0

1

Mathurin Fumery

@MatFume

1 year

RT @JCC_IBD: #Vedolizumab or #ustekinumab after anti-TNF failure in #UC ? A French #RWE comparison. @MatFume @anthonybuisson . https://t.co….

0

4

0